PM01183 Completa la Fase I para el Tratamiento de Leucemia . Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome .

*.- Health Authority: United States: Food and Drug Administration .

*.- This study has been completed .


*.- Sponsor: PharmaMar .


*.- Last updated: July 27, 2015 .


*.- Last verified: July 2015 .



Enrollment: 45
Study Start Date: May 2011
Study Completion Date: July 2015
Primary Completion Date: July 2015 (Final data collection date for primary outcome measure)

*.- Locations :

* United States, Minnesota
Rochester, Minnesota, United States, 55905

* United States, Texas
Houston, Texas, United States, 77030